CatalystFDA/Bio

Upstream Bio stock jumps 8% on Phase 2 severe asthma data

Phase 2 severe asthma data triggered an 8% stock jump.

What changed

Phase 2 severe asthma data triggered an 8% stock jump.

Why it matters

Phase 2 severe asthma data triggered an 8% stock jump. — impact context not separately stored; see What changed.

Sources